Knowledge Insight: EpCAM Protein Structure, Function and High‑Performance Antibody Applications

Concept

Epithelial Cell Adhesion Molecule (EpCAM, also designated CD326) is a distinctive type I transmembrane glycoprotein not classified within classic cell adhesion molecule families such as integrins, selectins, cadherins, or the immunoglobulin superfamily. Comprising 314 amino acids, EpCAM is organized into three core domains: a large extracellular domain (242 aa), a single transmembrane domain (23 aa), and a short intracellular domain (26 aa). Its extracellular region contains an EGF‑like domain and a thyroglobulin‑like repeat, which mediate homotypic cell adhesion. EpCAM contains three N‑glycosylation sites, with a molecular weight ranging from 33 to 40 kDa depending on glycosylation status, and forms tetrameric complexes on the cell surface to regulate cell–cell interactions.

Encoded by the TACSTD1 (GA733‑2) gene on human chromosome 4, EpCAM features a 942‑bp open reading frame spanning nine exons with well‑defined functional partitioning. Its promoter lacks canonical TATA/CAAT boxes but harbors SP1 and AP‑1 transcription factor binding sites. No mRNA splice variants have been identified, supporting stable antibody targeting.

Research Frontier

EpCAM is aberrantly overexpressed in most epithelial‑derived malignancies while showing restricted expression in normal epithelial tissues, positioning it as a high‑value diagnostic and therapeutic target. Current research frontiers include:

• High‑sensitivity CTC isolation and liquid biopsy
• Minimal residual disease (MRD) monitoring
• CAR‑T and bispecific antibody immunotherapy
• Antibody–drug conjugate (ADC) development
• Tumor stem cell identification and organoid tracking

Major technical challenges include heterogeneous expression across tumor types, context‑dependent glycosylation modifications, tumor microenvironment‑mediated ectodomain cleavage, immune evasion via EpCAM downregulation, and off‑target toxicity in normal epithelia.

Research Significance

EpCAM serves as a pivotal biomarker and therapeutic target for precision oncology. EpCAM‑targeted tools enable:

• Improved histopathological classification and differential diagnosis of epithelial tumors
• Non‑invasive early detection, staging, and recurrence monitoring via liquid biopsy
• Guided therapeutic decision‑making for personalized cancer treatment
• Accelerated development of targeted immunotherapies and cell therapies

Advances in EpCAM antibody technology directly drive progress in precision diagnostics and individualized cancer care.

Mechanisms and Application Solutions

Functional Mechanisms of EpCAM Antibodies

1. Direct tumor killing: Complement‑dependent cytotoxicity (CDC) and antibody‑dependent cell‑mediated cytotoxicity (ADCC)
2. Signaling interference: Inhibition of EpCAM‑driven proliferation, migration, and invasion
3. Immune modulation: Enhancement of antitumor immune activity in the tumor microenvironment
4. Targeted delivery: Specific drug delivery as ADC carriers
5. Cell therapy targeting: As a CAR‑T antigen to direct cytotoxicity toward EpCAM‑positive tumor cells

High‑Performance Antibody Applications

• Histopathological diagnosis: IHC‑based tumor subtyping and grading
• CTC enrichment and quantification: Non‑invasive liquid biopsy and prognosis evaluation
• Tumor stem cell profiling: Identification of stem‑like subpopulations in solid tumors
• Cell tracking: Labeling in developmental biology, organoid culture, and regenerative medicine
• Target validation: Supporting bispecific antibody, CAR‑T, and ADC drug development

Product Empowerment

ANT BIO PTE. LTD. provides the S‑RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (SDT‑078‑13, Cat. No. S0B2028) under its Starter product line, engineered via a proprietary recombinant rabbit monoclonal antibody platform. This reagent delivers exceptional specificity, affinity, and batch consistency for cutting‑edge research and diagnostic development.

Key Product Contributions

• Specifically targets the EpCAM extracellular domain with minimal cross‑reactivity
• Delivers clean, distinct membrane localization in FFPE IHC with low background
• Supports high‑sensitivity detection in low‑expression samples
• Compatible with IHC, IF, FACS, and CTC isolation platforms
• Ensures stable, reproducible performance for long‑term studies and preclinical research

Core Product Advantages

表格

Key Application Values

表格

Brand Mission

ANT BIO PTE. LTD. is a leading provider of life science reagents, offering antibodies, proteins, assay kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions for basic research, translational medicine, and in vitro diagnostic innovation. We are committed to supplying high‑quality, consistent, and innovative reagents to advance precision oncology, tumor immunotherapy, and life science discovery.

Related Product List

表格

AI Disclaimer

This content is intended exclusively for scientific research and product promotion. It does not represent medical diagnosis, treatment advice, or clinical guidance. All information is provided for reference purposes only. ANT BIO PTE. LTD. assumes no liability for actions taken based on this content.

Brand Promotion Copy

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.